

# Respiratory Expertise

**Illingworth Research Group has a long history working in respiratory clinical trials. Our team has a comprehensive pedigree and are considered experts in this therapeutic area, both in device and drug studies. These studies have been conducted in both primary and secondary care settings.**

Over the years, we have developed a bespoke respiratory team consisting of highly experienced respiratory Project Managers and Research Nurses who work on phase I - IV studies as well as offering support to patients requiring study visits away from the site.

Yvonne Meades, a senior member of the respiratory team at Illingworth commented *“one of the reasons that clients like us is that we have specialist knowledge. We go to site and know how to read spirometry results and cough challenge data without the site having to train us”.*



*“I would consider Illingworth Research experts in this indication and they have established strong relationships with key investigators. They have been a true partner with open, honest communication, exhibiting a high degree of professionalism and flexibility.”*

**Quote from the Sponsor, Vice President, Clinical Operations.**

*“I have no hesitation in recommending Illingworth Research. I have always found them to be professional, trustworthy and approachable. The team have a wide knowledge of differing therapeutic areas but particularly excel in the Respiratory arena.*

**Quote from Director of Operations, MEU (Medicines Evaluation Unit)**

We work with the biopharmaceutical industry to support the development of potential new treatments and devices for conditions such as:

- **Acute respiratory distress syndrome (ARDS)**
- **Allergies**- including a variety of allergen challenge studies
- **Asthma** - including studies in asthma due to house dust mite allergy, observational studies, asthma allergen challenge, persistent asthma and uncontrolled asthma with patients hospitalised in Intensive Care Units
- **Chronic Refractory Cough** - including phase I-III cough programmes and cough challenge studies involving the inhalation of tussive agents/ substances such as ATP, Capsaicin, Citric Acid and Distilled Water. These substances were inhaled via a nebulizer, controlled by the KoKo DigiDoser and the number of induced coughs counted.
- **Chronic Obstructive Pulmonary Disease (COPD)**
- **Cystic Fibrosis**
- **Idiopathic Pulmonary Fibrosis** - including management of the cough count monitors and off-site research nursing support
- **Post-Operative Recovery -Medical Device**
- **Respiratory Syncytial Virus (RSV)** - including an RSV challenge study.



Illingworth has over 20 years of experience working with a leading specialist clinical research facility in Manchester. Specialising in a variety of respiratory indications, their Principal Investigator, Professor Dave Singh is a Key Opinion Leader and world-renowned expert in the respiratory field.